Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Medicina (B Aires) ; 73(5): 423-7, 2013.
Artigo em Espanhol | MEDLINE | ID: mdl-24152397

RESUMO

In previous reports, psoriasis was associated with an increased rate of coronary artery disease. These data has not been investigated in our population. We performed a cross-sectional study analyzing data from electronic medical records of a health system in Buenos Aires. We included all patients older than 18 years diagnosed with psoriasis between January 1, 2003 and July 31, 2011 and compared them with a control group. Controls were selected randomly by strata of age and sex from the same health system in a 2:1 ratio. We determined the prevalence of cardiovascular risk factors and coronary heart disease. We analyzed the association between psoriasis and coronary artery disease by both univariate and multivariate analyzes. In total, 3 833 subjects were included (1 286 with psoriasis and 2 547 controls). The prevalence of hypertension (50% vs. 38%, p < 0.001), smoking (25% vs. 17%, p < 0.001), diabetes (12% vs. 8%, p < 0.001) and coronary artery disease (4.98% vs. 3.06%, p = 0.003) were higher in the psoriasis group compared to controls. Regardless age and the presence or absence of diabetes, hypertension or smoking, there was a significant association between coronary artery disease and psoriasis (OR 1.48, CI95% 1.04-2.11, p = 0.03). In conclusion, in this population of Buenos Aires, psoriasis patients had a higher prevalence of diabetes, hypertension, smoking, and coronary artery disease. The association between psoriasis and coronary artery disease was independent of the risk factors explored.


Assuntos
Doença da Artéria Coronariana/etiologia , Psoríase/complicações , Adulto , Idoso , Argentina/epidemiologia , Estudos de Casos e Controles , Doença da Artéria Coronariana/epidemiologia , Estudos Transversais , Complicações do Diabetes/epidemiologia , Registros Eletrônicos de Saúde , Feminino , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Prevalência , Psoríase/epidemiologia , Fatores de Risco , Distribuição por Sexo , Fumar/efeitos adversos , Fumar/epidemiologia , Estatísticas não Paramétricas
2.
An Bras Dermatol ; 95(1): 20-24, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31899062

RESUMO

BACKGROUND: Despite the economic burden of psoriasis for patients and societies, scant information exists regarding the impact and burden of the disease in Argentina. OBJECTIVE: The objective of this study was to estimate medical resource consumption and direct health care costs for patients with moderate/severe psoriasis in Buenos Aires, Argentina from the perspective of the payer. METHODS: Adults with moderate/severe psoriasis (severity was defined as receiving systemic treatment), during January 2010-January 2014, aged 18 years and older, members of the Italian Hospital Medical Care Program with at least 18 months of follow-up were included. All data on hospitalizations, drug prescription, outpatient episodes, consultations, and investigations/tests in the 12 months before inclusion in the study were considered for the estimation of medical resource consumption and direct health care costs. First-quarter 2018 costs were obtained from the IHMCP and converted into US dollars (using the January 2018 exchange rate). RESULTS: A total of 791 patients were included. The mean age at diagnosis was 34±12 years. Almost 65% of the patients had a dermatologist as their usual source of care, 43% had internists, and 14% had rheumatologists. The average yearly direct cost was US$ 5326 (95% CI: 4125-7896) per patient per year. STUDY LIMITATION: The single center design and the retrospective nature are the main limitations. CONCLUSION: This is the first Argentine study that evaluated the costs of moderate/severe psoriasis by taking into consideration the direct medical costs of the disease.


Assuntos
Custos de Cuidados de Saúde/estatística & dados numéricos , Psoríase/economia , Adulto , Argentina , Prescrições de Medicamentos/economia , Feminino , Hospitalização/economia , Humanos , Masculino , Pessoa de Meia-Idade , Encaminhamento e Consulta/economia , Estudos Retrospectivos , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Fatores de Tempo , Adulto Jovem
3.
Int J Dermatol ; 56(4): 386-391, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28295267

RESUMO

OBJECTIVE: The aim of this study was to describe the clinical characteristics of patients with pyoderma gangrenosum (PG) and to evaluate the association between these characteristics, the treatment followed, and the patient responses, relapses, and mortality rates. MATERIAL AND METHODS: This retrospective cohort study identified adults diagnosed with pyoderma gangrenosum over the duration of 10 years. RESULTS: Thirty-one patients were evaluated; 58% were women and 55% were older than 65 years, 87% presented with the ulcerative type, and 77% showed lower limb compromise. Approximately 74% of the cases were associated with systemic disease. The most frequent were inflammatory bowel disease (32%) and hematologic malignancies (22%). Pyoderma gangrenosum preceded the associated disease in 26% of the patients, all of them were younger than 50 years old (P = 0.059). In 83% of the latter, the diagnosis of associated disease followed the cutaneous lesions within 24 months. Among the 10 patients with inflammatory bowel disease, six required biologic agents to control the pyoderma gangrenosum (P = 0.002). CONCLUSION: Despite the advances that have been made in the treatment of patients with pyoderma gangrenosum, we are still unclear as to the optimal way in which patients should be followed up once the diagnosis is made. The results of our study underline the importance of doing screening tests to detect potential disease, emphasizing patients younger than 50 years old, for a minimum time lapse of 24 months. It is essential to design randomized-controlled trials to understand the most appropriate and effective ways of following up patients with pyoderma gangrenosum.


Assuntos
Glucocorticoides/uso terapêutico , Neoplasias Hematológicas/complicações , Doenças Inflamatórias Intestinais/complicações , Prednisona/uso terapêutico , Pioderma Gangrenoso/complicações , Pioderma Gangrenoso/tratamento farmacológico , Adalimumab/uso terapêutico , Adulto , Fatores Etários , Idoso , Artrite Reumatoide/complicações , Artrite Reumatoide/diagnóstico , Ciclosporina/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Etanercepte/uso terapêutico , Feminino , Neoplasias Hematológicas/diagnóstico , Humanos , Doenças Inflamatórias Intestinais/diagnóstico , Infliximab/uso terapêutico , Masculino , Pessoa de Meia-Idade , Pioderma Gangrenoso/diagnóstico , Estudos Retrospectivos , Fatores Sexuais , Taxa de Sobrevida
4.
Int J Dermatol ; 56(4): 415-420, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28295266

RESUMO

BACKGROUND: Phaeohyphomycosis is an infrequent infection in human beings. However, in recent years, its prevalence has augmented in immunosuppressed patients (mostly in solid organ transplanted patients). Infection can be mucocutaneous or disseminated. In the former, the fungus inoculation occurs mainly through traumatism. Lesions may be polymorphic and asymptomatic, isolated or multiple, and are usually localized in exposed areas of the limbs and head. Treatment is not standardized. When possible, surgical resection of the lesion is combined with systemic antifungals. METHODS: We communicate three phaeohyphomycosis cases with cutaneous compromise. RESULTS: The cases we present show diverse clinical characteristics and varied severity and evolution. CONCLUSION: It is important for dermatologists to recognize this cutaneous fungus infection because the diagnosis using microscopic examination and mycological culture depends on the clinical suspicion.


Assuntos
Dermatomicoses/microbiologia , Dermatomicoses/terapia , Fasciite Necrosante/microbiologia , Hospedeiro Imunocomprometido , Feoifomicose/imunologia , Feoifomicose/terapia , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Dermatomicoses/diagnóstico , Evolução Fatal , Feminino , Humanos , Itraconazol/uso terapêutico , Pneumopatias/microbiologia , Masculino , Pessoa de Meia-Idade , Feoifomicose/microbiologia , Feoifomicose/patologia
5.
An. bras. dermatol ; 95(1): 20-24, Jan.-Feb. 2020. tab
Artigo em Inglês | LILACS | ID: biblio-1088726

RESUMO

Abstract Background: Despite the economic burden of psoriasis for patients and societies, scant information exists regarding the impact and burden of the disease in Argentina. Objective: The objective of this study was to estimate medical resource consumption and direct health care costs for patients with moderate/severe psoriasis in Buenos Aires, Argentina from the perspective of the payer. Methods: Adults with moderate/severe psoriasis (severity was defined as receiving systemic treatment), during January 2010-January 2014, aged 18 years and older, members of the Italian Hospital Medical Care Program with at least 18 months of follow-up were included. All data on hospitalizations, drug prescription, outpatient episodes, consultations, and investigations/tests in the 12 months before inclusion in the study were considered for the estimation of medical resource consumption and direct health care costs. First-quarter 2018 costs were obtained from the IHMCP and converted into US dollars (using the January 2018 exchange rate). Results: A total of 791 patients were included. The mean age at diagnosis was 34 ± 12 years. Almost 65% of the patients had a dermatologist as their usual source of care, 43% had internists, and 14% had rheumatologists. The average yearly direct cost was US$ 5326 (95% CI: 4125-7896) per patient per year. Study limitation: The single center design and the retrospective nature are the main limitations. Conclusion: This is the first Argentine study that evaluated the costs of moderate/severe psoriasis by taking into consideration the direct medical costs of the disease.


Assuntos
Humanos , Masculino , Feminino , Adulto , Adulto Jovem , Psoríase/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Argentina , Prescrições de Medicamentos/economia , Encaminhamento e Consulta/economia , Fatores de Tempo , Índice de Gravidade de Doença , Estudos Retrospectivos , Estatísticas não Paramétricas , Hospitalização/economia , Pessoa de Meia-Idade
6.
Int J Dermatol ; 53(7): 912-6, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24602108

RESUMO

BACKGROUND: All-trans retinoic acid (ATRA) is routinely associated with chemotherapy for the treatment of acute promyelocytic leukemia (APL). Several reports of scrotal ulceration induced by this agent have been made in the recent years. AIMS: The aim of this article was to report the first case of a lingual ulceration associated with retinoic acid syndrome (RAS). MATHERIALS AND METHODS: We presented a 32-year-old man with a diagnosis of acute promyelocytic leukemia who received treatment with ATRA. He presented with febrile neutropenia and a lingual ulcer that did not respond to antibiotic and antifungal regimens. He developed weight gain, lower limb edema, polyserositis, and acute renal failure. Retinoic acid syndrome syndrome was diagnosed. RESULTS: An exhaustive attempt to exclude infectious causes was made performing repeated cultures, histologic examinations, and direct immunofluorescence for HSV. No causative agent was identified. Re-epithelialization of the ulcer was achieved with ATRA cessation and treatment with systemic steroids. DISCUSSION: As far as we are concerned, we report the first case of a lingual ulceration associated with RAS. CONCLUSION: It is important for dermatologists to recognize this cutaneous complication of ATRA as it poses many differential diagnoses in neutropenic patients.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Leucemia Promielocítica Aguda/tratamento farmacológico , Úlceras Orais/induzido quimicamente , Doenças da Língua/induzido quimicamente , Injúria Renal Aguda/induzido quimicamente , Adulto , Neutropenia Febril/induzido quimicamente , Humanos , Idarubicina/administração & dosagem , Masculino , Úlceras Orais/patologia , Síndrome , Doenças da Língua/patologia , Tretinoína/administração & dosagem , Tretinoína/efeitos adversos
7.
Int J Dermatol ; 51(7): 829-34, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22715827

RESUMO

BACKGROUND: Chagas' disease is a zoonosis caused by a protozoan agent, Trypanosoma cruzi. Patients undergoing immunosuppressive treatment due to organ transplant, malignancies, infections, or chemotherapy may reactivate a preexisting chronic or indeterminate Trypanosoma cruzi infection. METHODS: We present two transplant patients who underwent reactivation of Chagas' disease with cutaneous manifestations after an augmentation in their immunosuppressive therapy. A 38-year-old man was hospitalized on day 69 after receiving an allogeneic bone marrow transplant; he developed multiple painful erythematous plaques with diffuse borders, confined to the right cheek, trunk, thigh, elbows, and feet. A 59-year-old woman with a 14-year history of Chagasic cardiomyopathy presented one month after heart transplantation with a painful infiltrated purpuric plaque on the back of her right leg. RESULTS: In both cases, histologic examination of skin biopsies showed dermal infiltration with intrahistiocytic amastigotes. In one of the reported cases, the Strout method detected parasitemia. Treatments with nifurtimox (600 mg/d) in case 1 and benznidazole (400 mg/d) in case 2 were started. Fever and cutaneous lesions resolved immediately after seven days of treatment. CONCLUSIONS: Reactivation of Chagas' disease is a serious complication that usually occurs in immunocompromised patients. Clinical manifestations include febrile illness occasionally associated with painful skin lesions. Early diagnosis and proper treatment can significantly improve these patients' outcome.


Assuntos
Doença de Chagas/imunologia , Hospedeiro Imunocomprometido , Adulto , Transplante de Medula Óssea/efeitos adversos , Doença de Chagas/tratamento farmacológico , Doença de Chagas/patologia , Feminino , Transplante de Coração/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , Masculino , Pessoa de Meia-Idade , Nifurtimox/uso terapêutico , Nitroimidazóis/uso terapêutico , Recidiva , Tripanossomicidas/uso terapêutico
8.
Arch Drug Inf ; 2(4): 71-78, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20098510

RESUMO

INTRODUCTION: Psoriasis is a debilitating, chronic inflammatory systemic disease affecting around 2% of the South American population. Biological therapies offer the possibility of long-term therapy with improved safety and efficacy. METHODS: We conducted a multicentre, open-label, single-arm, Phase IIIb/IV study of adult patients (18-75 years) with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. Patients received efalizumab subcutaneously (1.0 mg/kg/wk). The primary endpoint was the proportion of patients achieving a Physician Global Assessment (PGA) rating of "excellent" or "cleared" at Week 24. Safety outcomes were adverse events (AEs), serious AEs (SAEs) and abnormalities on laboratory tests. RESULTS: Of 189 patients included in the intent-to-treat and safety populations, 104 (55.0%) were of Hispanic or Latino ethnicity. At Week 24, 92/189 (48.7%) patients achieved or maintained a PGA rating of "excellent" or "cleared". AEs were reported by 161/189 (85.2%) patients, SAEs by 21/189 (11.1%). One patient died during the study (meningoencephalitis). Laboratory findings were consistent with previous experience. CONCLUSIONS: Efalizumab demonstrated sustained control of psoriasis up to 24 weeks in patients from Latin America, confirming results seen in Phase III studies conducted in North America and Europe.

9.
Medicina (B.Aires) ; 73(5): 423-427, oct. 2013. graf, tab
Artigo em Espanhol | BINACIS | ID: bin-130315

RESUMO

Comunicaciones previas asociaron la psoriasis con la enfermedad coronaria. Desconocemos si en nuestro país o región existe dicha asociación. Se realizó un estudio transversal analizando los datos de la historia clínica electrónica de un sistema de salud de Buenos Aires. Analizamos todos los pacientes mayores de 18 años con diagnóstico de psoriasis entre el 1 de enero de 2003 y el 31 de julio de 2011 y los comparamos con un grupo control, en una relación 2:1, obtenido en forma aleatoria del mismo sistema de salud, apareados por edad y sexo. Determinamos la prevalencia de los factores de riesgo cardiovascular y de enfermedad coronaria. Analizamos la asociación entre la enfermedad coronaria y la psoriasis mediante análisis uni y multivariado. Se incluyeron 3 833 sujetos (1 286 pacientes con psoriasis y 2 547 controles). La prevalencia de hipertensión arterial (50% vs. 38%, p < 0.001), tabaquismo (25% vs. 17%, p < 0.001), diabetes (12% vs. 8%, p < 0.001) y enfermedad coronaria (4.98% vs. 3.06%, p = 0.003) fue mayor en los sujetos con psoriasis en comparación con el grupo control. Independientemente de la edad, la presencia de diabetes, hipertensión arterial o tabaquismo, hubo una asociación significativa entre la enfermedad coronaria y la psoriasis (OR 1.48, IC95% 1.04-2.11, p = 0.03). En conclusión, en esta población de Buenos Aires, los pacientes con psoriasis tuvieron una mayor prevalencia de diabetes, hipertensión arterial, tabaquismo y enfermedad coronaria. La asociación entre la psoriasis y la enfermedad coronaria fue independiente de los factores de riesgo explorados.(AU)


In previous reports, psoriasis was associated with an increased rate of coronary artery disease. These data has not been investigated in our population. We performed a cross-sectional study analyzing data from electronic medical records of a health system in Buenos Aires. We included all patients older than 18 years diagnosed with psoriasis between January 1, 2003 and July 31, 2011 and compared them with a control group. Controls were selected randomly by strata of age and sex from the same health system in a 2:1 ratio. We determined the prevalence of cardiovascular risk factors and coronary heart disease. We analyzed the association between psoriasis and coronary artery disease by both univariate and multivariate analyzes. In total, 3 833 subjects were included (1 286 with psoriasis and 2 547 controls). The prevalence of hypertension (50% vs. 38%, p < 0.001), smoking (25% vs. 17%, p < 0.001), diabetes (12% vs. 8%, p < 0.001) and coronary artery disease (4.98% vs. 3.06%, p = 0.003) were higher in the psoriasis group compared to controls. Regardless age and the presence or absence of diabetes, hypertension or smoking, there was a significant association between coronary artery disease and psoriasis (OR 1.48, CI95% 1.04-2.11, p = 0.03). In conclusion, in this population of Buenos Aires, psoriasis patients had a higher prevalence of diabetes, hypertension, smoking, and coronary artery disease. The association between psoriasis and coronary artery disease was independent of the risk factors explored.(AU)


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença da Artéria Coronariana/etiologia , Psoríase/complicações , Argentina/epidemiologia , Estudos de Casos e Controles , Doença da Artéria Coronariana/epidemiologia , Estudos Transversais , Complicações do Diabetes/epidemiologia , Registros Eletrônicos de Saúde , Hipertensão/complicações , Hipertensão/epidemiologia , Análise Multivariada , Prevalência , Psoríase/epidemiologia , Fatores de Risco , Distribuição por Sexo , Fumar/efeitos adversos , Fumar/epidemiologia , Estatísticas não Paramétricas
10.
Medicina (B.Aires) ; 73(5): 423-427, oct. 2013. graf, tab
Artigo em Espanhol | LILACS | ID: lil-708528

RESUMO

Comunicaciones previas asociaron la psoriasis con la enfermedad coronaria. Desconocemos si en nuestro país o región existe dicha asociación. Se realizó un estudio transversal analizando los datos de la historia clínica electrónica de un sistema de salud de Buenos Aires. Analizamos todos los pacientes mayores de 18 años con diagnóstico de psoriasis entre el 1 de enero de 2003 y el 31 de julio de 2011 y los comparamos con un grupo control, en una relación 2:1, obtenido en forma aleatoria del mismo sistema de salud, apareados por edad y sexo. Determinamos la prevalencia de los factores de riesgo cardiovascular y de enfermedad coronaria. Analizamos la asociación entre la enfermedad coronaria y la psoriasis mediante análisis uni y multivariado. Se incluyeron 3 833 sujetos (1 286 pacientes con psoriasis y 2 547 controles). La prevalencia de hipertensión arterial (50% vs. 38%, p < 0.001), tabaquismo (25% vs. 17%, p < 0.001), diabetes (12% vs. 8%, p < 0.001) y enfermedad coronaria (4.98% vs. 3.06%, p = 0.003) fue mayor en los sujetos con psoriasis en comparación con el grupo control. Independientemente de la edad, la presencia de diabetes, hipertensión arterial o tabaquismo, hubo una asociación significativa entre la enfermedad coronaria y la psoriasis (OR 1.48, IC95% 1.04-2.11, p = 0.03). En conclusión, en esta población de Buenos Aires, los pacientes con psoriasis tuvieron una mayor prevalencia de diabetes, hipertensión arterial, tabaquismo y enfermedad coronaria. La asociación entre la psoriasis y la enfermedad coronaria fue independiente de los factores de riesgo explorados.


In previous reports, psoriasis was associated with an increased rate of coronary artery disease. These data has not been investigated in our population. We performed a cross-sectional study analyzing data from electronic medical records of a health system in Buenos Aires. We included all patients older than 18 years diagnosed with psoriasis between January 1, 2003 and July 31, 2011 and compared them with a control group. Controls were selected randomly by strata of age and sex from the same health system in a 2:1 ratio. We determined the prevalence of cardiovascular risk factors and coronary heart disease. We analyzed the association between psoriasis and coronary artery disease by both univariate and multivariate analyzes. In total, 3 833 subjects were included (1 286 with psoriasis and 2 547 controls). The prevalence of hypertension (50% vs. 38%, p < 0.001), smoking (25% vs. 17%, p < 0.001), diabetes (12% vs. 8%, p < 0.001) and coronary artery disease (4.98% vs. 3.06%, p = 0.003) were higher in the psoriasis group compared to controls. Regardless age and the presence or absence of diabetes, hypertension or smoking, there was a significant association between coronary artery disease and psoriasis (OR 1.48, CI95% 1.04-2.11, p = 0.03). In conclusion, in this population of Buenos Aires, psoriasis patients had a higher prevalence of diabetes, hypertension, smoking, and coronary artery disease. The association between psoriasis and coronary artery disease was independent of the risk factors explored.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença da Artéria Coronariana/etiologia , Psoríase/complicações , Argentina/epidemiologia , Estudos de Casos e Controles , Estudos Transversais , Doença da Artéria Coronariana/epidemiologia , Complicações do Diabetes/epidemiologia , Registros Eletrônicos de Saúde , Hipertensão/complicações , Hipertensão/epidemiologia , Análise Multivariada , Prevalência , Psoríase/epidemiologia , Fatores de Risco , Distribuição por Sexo , Estatísticas não Paramétricas , Fumar/efeitos adversos , Fumar/epidemiologia
14.
Dermatol. argent ; 12(4): 291-294, dic. 2006. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-558676

RESUMO

El escleredema es una entidad infrecuente de etiología desconocida, que se caracteriza por el engrosamiento de la piel del cuello, los hombros y la espalda. Generalmente se observa en pacientes diabéticos. Presentamos el caso de un varón de 74 años, diabético tipo II, que cursa internación en la unidad de cuidados intensivos por un accidente cerebro-vascular y neumonía grave. Al examen dermatológico presentaba una placa de escleredema en cuello, hombros y parte alta del dorso, sobre la que asentaba una úlcera provocada por el decúbito obligado.


Assuntos
Humanos , Masculino , Idoso , /complicações , Escleredema do Adulto/classificação , Escleredema do Adulto/complicações , Escleredema do Adulto/etiologia
15.
Rev. Hosp. Ital. B.Aires ; 6(4): 180-88, dic. 1986. tab
Artigo em Espanhol | LILACS | ID: lil-103284

RESUMO

Mil siete pacientes adultos portadores de dermatomicosis fueron incluidos en este estudio abierto y multicéntrico desarrollado en Argentina y Uruguay. Los objetivos del estudio fueron determinar la efectividad terapéutica y la tolerancia de cada una de las presentaciones de bifonazole (crema, solución, gél), todas conteniendo 1% de sustancia activa, después de una aplicación diaria durante dos, tres o cuatro semanas de tratamiento. La duración del tratamiento se fijó para cada indicación en particular y para cada formulación del bifonazole. Los resultados obtenidos fueron los seguientes: Tinea pedis interdigitalis 19%; Tinea corporis + Tinea cruris 89%; Pitiriasis versicolor 88%; Candidiasis superficiales 80%; Dermatitis del pañal 64%. Se observaron efectos secundarios en once pacientes (1%); los síntomas más frecuentes fueron ardor y eritema. Tres pacientes interrumpieron el tratamiento debido a la persistencia e intensidad de los síntomas


Assuntos
Adulto , Humanos , Dermatomicoses/tratamento farmacológico , Imidazóis/uso terapêutico , Argentina , Ensaios Clínicos como Assunto , Imidazóis/administração & dosagem , Estudos Multicêntricos como Assunto , Uruguai
16.
Rev. Hosp. Ital. B.Aires ; 6(4): 180-88, dic. 1986. tab
Artigo em Espanhol | BINACIS | ID: bin-26714

RESUMO

Mil siete pacientes adultos portadores de dermatomicosis fueron incluidos en este estudio abierto y multicéntrico desarrollado en Argentina y Uruguay. Los objetivos del estudio fueron determinar la efectividad terapéutica y la tolerancia de cada una de las presentaciones de bifonazole (crema, solución, gél), todas conteniendo 1% de sustancia activa, después de una aplicación diaria durante dos, tres o cuatro semanas de tratamiento. La duración del tratamiento se fijó para cada indicación en particular y para cada formulación del bifonazole. Los resultados obtenidos fueron los seguientes: Tinea pedis interdigitalis 19%; Tinea corporis + Tinea cruris 89%; Pitiriasis versicolor 88%; Candidiasis superficiales 80%; Dermatitis del pañal 64%. Se observaron efectos secundarios en once pacientes (1%); los síntomas más frecuentes fueron ardor y eritema. Tres pacientes interrumpieron el tratamiento debido a la persistencia e intensidad de los síntomas (AU)


Assuntos
Adulto , Humanos , Dermatomicoses/tratamento farmacológico , Imidazóis/uso terapêutico , Imidazóis/administração & dosagem , Estudos Multicêntricos como Assunto , Ensaios Clínicos como Assunto , Argentina , Uruguai
17.
Medicina (B Aires) ; 73(5): 423-7, 2013.
Artigo em Espanhol | BINACIS | ID: bin-132910

RESUMO

In previous reports, psoriasis was associated with an increased rate of coronary artery disease. These data has not been investigated in our population. We performed a cross-sectional study analyzing data from electronic medical records of a health system in Buenos Aires. We included all patients older than 18 years diagnosed with psoriasis between January 1, 2003 and July 31, 2011 and compared them with a control group. Controls were selected randomly by strata of age and sex from the same health system in a 2:1 ratio. We determined the prevalence of cardiovascular risk factors and coronary heart disease. We analyzed the association between psoriasis and coronary artery disease by both univariate and multivariate analyzes. In total, 3 833 subjects were included (1 286 with psoriasis and 2 547 controls). The prevalence of hypertension (50


vs. 38


, p < 0.001), smoking (25


vs. 17


, p < 0.001), diabetes (12


vs. 8


, p < 0.001) and coronary artery disease (4.98


vs. 3.06


, p = 0.003) were higher in the psoriasis group compared to controls. Regardless age and the presence or absence of diabetes, hypertension or smoking, there was a significant association between coronary artery disease and psoriasis (OR 1.48, CI95


1.04-2.11, p = 0.03). In conclusion, in this population of Buenos Aires, psoriasis patients had a higher prevalence of diabetes, hypertension, smoking, and coronary artery disease. The association between psoriasis and coronary artery disease was independent of the risk factors explored.


Assuntos
Doença da Artéria Coronariana/etiologia , Psoríase/complicações , Adulto , Idoso , Argentina/epidemiologia , Estudos de Casos e Controles , Doença da Artéria Coronariana/epidemiologia , Estudos Transversais , Complicações do Diabetes/epidemiologia , Registros Eletrônicos de Saúde , Feminino , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Prevalência , Psoríase/epidemiologia , Fatores de Risco , Distribuição por Sexo , Fumar/efeitos adversos , Fumar/epidemiologia , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA